Haghshenas Mohammad Reza, Mousavi Tahoora, Kheradmand Motahareh, Afshari Mahdi, Moosazadeh Mahmood
Department of Microbiology, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Student Research Committee, Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Int J Prev Med. 2017 Jun 1;8:44. doi: 10.4103/ijpvm.IJPVM_413_16. eCollection 2017.
Human papillomavirus (HPV) can induce cervical intraepithelial neoplasia (CIN). Vaccination against HPV can play an important role in CIN prevention. This study aims to estimate the efficacy of L1 protein vaccines (Cervarix and Gardasil) in CIN 1, 2, 3 risk reduction using meta-analysis. Relevant articles were identified by two independent researchers searching international databanks. After application of inclusion/exclusion criteria and quality assessment, eligible articles were entered into the final meta-analysis. Inverse variance method and fixed effect model were used to combine the results of the primary studies. The heterogeneity between the results was assessed using Cochrane and indices. Of 11,530 evidence identified during the primary search, three papers were found eligible for meta-analysis, including 7213 participants in the intervention groups and 7170 healthy controls. The efficacy (95% confidence interval) of HPV 6, 11, 16, 18 monovalent and quadrivalent vaccines against CIN 1, CIN 2, and CIN 3 were estimated as of 95% (88-98), 97% (85-99), and 95% (78-99), respectively. This study showed that L1 protein vaccines Cervarix and Gardasil are highly protective vaccines playing an effective role in the prevention of HPV 6, 11, 16, 18 which are responsible for CIN 1, CIN 2, and CIN 3.
人乳头瘤病毒(HPV)可诱发宫颈上皮内瘤变(CIN)。接种HPV疫苗在预防CIN方面可发挥重要作用。本研究旨在通过荟萃分析评估L1蛋白疫苗(希瑞适和加德西)在降低CIN 1、2、3风险方面的疗效。两名独立研究人员通过检索国际数据库来识别相关文章。在应用纳入/排除标准并进行质量评估后,符合条件的文章被纳入最终的荟萃分析。采用逆方差法和固定效应模型来合并主要研究的结果。使用Cochrane和 指数评估结果之间的异质性。在初步检索中识别出的11530条证据中,发现有三篇论文符合荟萃分析的条件,干预组包括7213名参与者,健康对照组包括7170名。HPV 6、11、16、18单价和四价疫苗针对CIN 1、CIN 2和CIN 3的疗效(95%置信区间)分别估计为95%(88 - 98)、97%(85 - 99)和95%(78 - 99)。本研究表明,L1蛋白疫苗希瑞适和加德西是高度保护性疫苗,在预防导致CIN 1、CIN 2和CIN 3的HPV 6、11、16、18方面发挥着有效作用。